Phase I Study Of LY2784544, a JAK2 Selective Inhibitor, In Patients With Myelofibrosis (MF), Polycythemia Vera (PV), and Essential Thrombocythemia (ET)
Srđan Verstovšek(Unknown), Josef T. Prchal(Huntsman Cancer Institute), Mohamed E. Salama(The University of Texas at San Antonio Health Science Center), Celine Pitou(Eli Lilly (United States)), Ruben A. Mesa(Atrium Health Wake Forest Baptist), Richard A Walgreen(Eli Lilly (United States)), Gregory L. Price(Eli Lilly (United States)), Annamaria H. Zimmermann(St Bartholomew's Hospital), Jennifer L K Giles(Eli Lilly (United States))
Cited by 24
Related Papers
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
|Cancer Cell|2005|3k
Long-Term Survival Results of a Randomized Trial Comparing Gemcitabine Plus Cisplatin, With Methotrexate, Vinblastine, Doxorubicin, Plus Cisplatin in Patients With Bladder Cancer
|Journal of Clinical Oncology|2005|1.9k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k